查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1473765

透析器市场- 按类型（高通量、低通量）、按材料（合成、纤维素基）、按用途（一次性、可重复使用）、按最终用途（中心、家庭透析） - 全球预测， 2024 年- 2032

Dialyzers Market - By Type (High-flux, Low-flux), By Material (Synthetic, Cellulose-based), By Usage (Disposable, Reusable), By End-use (In-center, Home Dialysis) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在医疗基础设施投资增加和人口老化的推动下，透析器市场规模预计在 2024 年至 2032 年期间将以 7% 的复合年增长率成长。与生活方式相关的危险因素的增加正在推动对肾臟替代治疗的需求不断增长以及血液透析中心和医院的快速扩张。

全球慢性肾臟病（CKD）盛行率的不断上升是该产业成长的另一个重要驱动力。根据国家医学图书馆的数据，慢性肾臟病影响全球 10% 以上的人口，超过 8 亿人。人口老化以及糖尿病和高血压发病率上升等因素导致需要透析治疗的慢性肾臟病患者数量激增。不断增长的患者群体需要采用透析器来促进肾臟替代治疗并改善患者的治疗结果。

此外，透析技术的进步，例如高效透析器和改进的生物相容性材料的开发，正在推动市场成长。这些技术创新能够在血液透析过程中更有效地去除血液中的废物和多余液体，从而提高治疗效果和患者舒适度。

透析器市场根据类型、材料、用途、最终用途和地区进行分类。

预计到2032 年，低通量透析器类型细分市场的行业规模将以6.6% 的复合年增长率增长。的血液透析过程中广泛使用。这些透析器也为血液透析治疗提供了经济高效的解决方案，推动了它们在全球医疗机构中的采用。

按材料细分，从2024 年到2032 年，合成透析器市场预计将以7.1% 的复合年增长率扩张。性材料製成的合成透析器具有卓越的性能和生物相容性。这些透析器也因其出色的清除率、降低的血液凝固风险以及与现代透析机的兼容性而成为全球血液透析中心和医院的首选

受中国、印度和日本慢性肾臟病率不断上升、医疗基础设施不断发展以及医疗支出不断增加的推动，亚太地区透析器产业预计到 2032 年复合年增长率将达到 8.1%。不断扩大的患者群体，加上政府改善医疗保健服务机会的倡议，正在推动该地区的市场成长。此外，透析技术的进步和主要市场参与者增加投资将有助于区域产品的吸收。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球慢性肾臟病盛行率不断上升
      • 透析器技术的技术进步
      • 对居家透析疗法的需求不断增长
    • 产业陷阱与挑战
      • 治疗费用高
      • 与透析治疗相关的併发症的风险
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析
  • 定价分析
  • 未来市场趋势
  • 缺口分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • 高通量透析器
  • 低通量透析器

第 6 章：市场估计与预测：按材料划分，2018 年 - 2032 年

  • 主要趋势
  • 合成的
  • 纤维素基

第 7 章：市场估计与预测：按用途分类，2018 年 - 2032 年

  • 主要趋势
  • 一次性的
  • 可重复使用的

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

  • 主要趋势
  • 中心
  • 居家透析

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Allmed Medical Care Holdings Limited.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • China Chengdu Wesley Biotech Co.
  • Dialifegroup
  • Farmasol
  • Fresenius SE & Co. KGaA
  • Kawasumi Laboratories Inc.
  • Medica Group
  • Medivators, Inc.
  • Medtronic plc
  • Nikkiso Co., Ltd
简介目录
Product Code: 4684

Dialyzers Market size is expected to grow at 7% CAGR during 2024-2032, driven by the rising investments in healthcare infrastructure, and aging population. The rise in lifestyle-related risk factors is driving the growing demand for renal replacement therapy and rapid expansion of hemodialysis centers and hospitals.

The increasing prevalence of chronic kidney diseases (CKD) worldwide is another significant driver for the industry growth. According to National Library of Medicine, chronic kidney disease impacts over 10% of the global population, exceeding 800 million individuals. Factors, such as aging population along with the rising incidence of diabetes and hypertension have led to a surge in the number of CKD patients requiring dialysis treatment. This growing patient pool necessitates the adoption of dialyzers to facilitate renal replacement therapy and improve patient outcomes.

Additionally, advancements in dialysis technology, such as the development of high-efficiency dialyzers and improved biocompatible materials, are driving the market growth. These technological innovations enable more efficient removal of waste products and excess fluids from the blood during hemodialysis procedures for enhancing treatment efficacy and patient comfort.

The dialyzers market is classified based on type, material, usage, end-use and region.

The industry size from the low-flux dialyzers type segment is expected to grow at 6.6% CAGR till 2032. This is due to their wide usage in hemodialysis procedures for patients with end-stage renal disease (ESRD) due to their ability to effectively remove waste products and excess fluids from the blood. These dialyzers also offer a cost-effective and efficient solution for hemodialysis treatment, driving their adoption in healthcare facilities worldwide.

By material segmentation, the synthetic dialyzers market is poised to expand at 7.1% CAGR from 2024 to 2032. Synthetic dialyzers, made from biocompatible materials like polysulfone or polyethersulfone membranes, offer superior performance and biocompatibility compared to traditional cellulose-based dialyzers. These dialyzers are also preferred in hemodialysis centers and hospitals globally for their excellent clearance rates, reduced risk of blood clotting, and compatibility with modern dialysis machines

Asia Pacific dialyzers industry is set to gain traction at 8.1% CAGR up to 2032, driven by the increasing prevalence of chronic kidney diseases, growing healthcare infrastructure, and rising healthcare expenditure in China, India, and Japan. The expanding patient pool, coupled with government initiatives to improve access to healthcare services are fueling the market growth in the region. Additionally, advancements in dialysis technology and increasing investments by key market players will contribute to the regional product uptake.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic kidney diseases globally
      • 3.2.1.2 Technological advancements in dialyzer technology
      • 3.2.1.3 Rising demand for home dialysis therapies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High treatment cost
      • 3.2.2.2 Risk of complications associated with dialysis treatments
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Pricing analysis
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 High-flux dialyzers
  • 5.3 Low-flux dialyzers

Chapter 6 Market Estimates and Forecast, By Material, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Synthetic
  • 6.3 Cellulose-based

Chapter 7 Market Estimates and Forecast, By Usage, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Disposable
  • 7.3 Reusable

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 In-center
  • 8.3 Home dialysis

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Allmed Medical Care Holdings Limited.
  • 10.2 Asahi Kasei Medical Co., Ltd.
  • 10.3 B. Braun Melsungen AG
  • 10.4 Baxter International Inc.
  • 10.5 China Chengdu Wesley Biotech Co.
  • 10.6 Dialifegroup
  • 10.7 Farmasol
  • 10.8 Fresenius SE & Co. KGaA
  • 10.9 Kawasumi Laboratories Inc.
  • 10.10 Medica Group
  • 10.11 Medivators, Inc.
  • 10.12 Medtronic plc
  • 10.13 Nikkiso Co., Ltd